MYND Life Sciences (XCNQ:MYND) Cash-to-Debt : 0.00 (As of Jul. 2024)

View and export this data going back to 2021. Start your Free Trial

What is MYND Life Sciences Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. MYND Life Sciences's cash to debt ratio for the quarter that ended in Jul. 2024 was 0.00.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, MYND Life Sciences couldn't pay off its debt using the cash in hand for the quarter that ended in Jul. 2024.

The historical rank and industry rank for MYND Life Sciences's Cash-to-Debt or its related term are showing as below:

During the past 3 years, MYND Life Sciences's highest Cash to Debt Ratio was 2.78. The lowest was 0.00. And the median was 0.21.

XCNQ:MYND's Cash-to-Debt is not ranked ^*
in the Biotechnology industry.
Industry Median: 7.56
* Ranked among companies with meaningful Cash-to-Debt only.

MYND Life Sciences Cash-to-Debt Historical Data

The historical data trend for MYND Life Sciences's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

MYND Life Sciences Cash-to-Debt Chart

MYND Life Sciences Annual Data

Trend

Oct21

Oct22

Oct23

Cash-to-Debt

0.82

MYND Life Sciences Quarterly Data
	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24
Cash-to-Debt	Get a 7-Day Free Trial										-	-	-	-	-

Competitive Comparison of MYND Life Sciences's Cash-to-Debt

For the Biotechnology subindustry, MYND Life Sciences's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MYND Life Sciences's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MYND Life Sciences's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where MYND Life Sciences's Cash-to-Debt falls into.

Save Embed

;

Save Embed

;

MYND Life Sciences Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

MYND Life Sciences's Cash to Debt Ratio for the fiscal year that ended in Oct. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	0	/	(3	+	0)
	=	0.00

MYND Life Sciences's Cash to Debt Ratio for the quarter that ended in Jul. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	0	/	(3	+	0)
	=	0.00

MYND Life Sciences (XCNQ:MYND) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

MYND Life Sciences Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of MYND Life Sciences's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

MYND Life Sciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MYND Life Sciences Inc (XCNQ:MYND) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

MYNDF:USA

Address

105-2248 Elgin Avenue, Port Coquitlam, BC, CAN, V3C 2B2

Website

https://www.myndsciences.com

MYND Life Sciences Inc is a medical biotech drug research and development company. The company is focused on neuro pharmaceutical and novel drug development, diagnostics, and vaccines and is developing new biological entities (NBEs) and new chemical entities (NCEs) and differentiates itself from other (bio)pharmaceutical companies by different molecular concepts for the applications of psilocybin analogs for overcoming diseases.